Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma

Lung Cancer

Volumn 83, Issue 2, 2014, Pages 259-264

  Sun, Jong Mu ^a   Lira, Maruja ^b   Pandya, Kinnari ^b   Choi, Yoon La ^a   Ahn, Jin Seok ^a   Mao, Mao ^b   Han, Joungho ^a   Park, Keunchil ^a   Ahn, Myung Ju ^a   Kim, Jhingook ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b PFIZER INC   (United States)

Author keywords

Anaplastic lymphoma kinase; Characteristic; Epidermal growth factor receptor; Non small cell lung cancer; Prevalence; Prognosis; ROS1

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA; K RAS PROTEIN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MENINGEAL METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MUTATION RATE; OVERALL SURVIVAL; PLEURA CAVITY; PLEURA METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SMOKING; SURVIVAL RATE; TREATMENT DURATION;

ANAPLASTIC LYMPHOMA KINASE; CHARACTERISTIC; EPIDERMAL GROWTH FACTOR RECEPTOR; NON-SMALL CELL LUNG CANCER; PREVALENCE; PROGNOSIS; ROS1;

ADENOCARCINOMA; DNA MUTATIONAL ANALYSIS; FEMALE; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SMOKING; SURVIVAL ANALYSIS; TRANSCRIPTOME;

EID: 84892899428     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.11.009     Document Type: Article

References (27)

1. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
2. Camidge D.R., Bang Y.J., Kwak E.L., Iafrate A.J., Varella-Garcia M., Fox S.B., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13:1011-1019.
3. Seto T., Kiura K., Nishio M., Nakagawa K., Maemondo M., Inoue A., et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 2013, 14:590-598.
4. Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crino L., Ahn M.J., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368:2385-2394.
5. Shaw A.T., Mehra R., Kim D.W., Felip E., Chow L.Q.M., Camidge D.R., et al. Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. J Clin Oncol 2013, 31(Suppl.). [abstr 8010].
6. Koivunen J.P., Mermel C., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J., et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008, 14:4275-4283.
7. Rodig S.J., Mino-Kenudson M., Dacic S., Yeap B.Y., Shaw A., Barletta J.A., et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009, 15:5216-5223.
8. Wong D.W., Leung E.L., So K.K., Tam I.Y., Sihoe A.D., Cheng L.C., et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009, 115:1723-1733.
9. Fukui T., Yatabe Y., Kobayashi Y., Tomizawa K., Ito S., Hatooka S., et al. Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer 2012, 77:319-325.
10. Takeuchi K., Choi Y.L., Soda M., Inamura K., Togashi Y., Hatano S., et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008, 14:6618-6624.
11. Kim H., Yoo S.B., Choe J.Y., Paik J.H., Xu X., Nitta H., et al. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol 2011, 6:1359-1366.
12. Conklin C.M., Craddock K.J., Have C., Laskin J., Couture C., Ionescu D.N. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol 2013, 8:45-51.
13. Wagner P.L., Stiedl A.C., Wilbertz T., Petersen K., Scheble V., Menon R., et al. Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma. Lung Cancer 2011, 74:118-123.
14. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
15. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27:4247-4253.
16. Sasaki T., Rodig S.J., Chirieac L.R., Janne P.A. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010, 46:1773-1780.
17. Paik J.H., Choi C.M., Kim H., Jang S.J., Choe G., Kim D.K., et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 2012, 76:403-409.
18. Wu S.G., Kuo Y.W., Chang Y.L., Shih J.Y., Chen Y.H., Tsai M.F., et al. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J Thorac Oncol 2012, 7:98-104.
19. Camidge D.R., Kono S.A., Lu X., Okuyama S., Baron A.E., Oton A.B., et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 2011, 6:774-780.
20. Lee J.O., Kim T.M., Lee S.H., Kim D.W., Kim S., Jeon Y.K., et al. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol 2011, 6:1474-1480.
21. Lee H.Y., Ahn H.K., Jeong J.Y., Kwon M.J., Han J.H., Sun J.M., et al. Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer. Lung Cancer 2013, 79:40-45.
22. Doebele R.C., Lu X., Sumey C., Maxson D.A., Weickhardt A.J., Oton A.B., et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 2012, 118:4502-4511.
23. Groome P.A., Bolejack V., Crowley J.J., Kennedy C., Krasnik M., Sobin L.H., et al. The IASLC lung cancer staging project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007, 2:694-705.
24. Lira M.E., Kim T.M., Huang D., Deng S., Koh Y., Jang B., et al. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. J Mol Diagn 2013, 15:51-61.
25. Cardarella S., Ogino A., Nishino M., Butaney M., Shen J., Lydon C., et al. Clinical, pathological and biological features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 2013, 19:4532-4540.
26. Bergethon K., Shaw A.T., Ou S.H., Katayama R., Lovly C.M., McDonald N.T., et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012, 30:863-870.
27. Ju Y.S., Lee W.C., Shin J.Y., Lee S., Bleazard T., Won J.K., et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 2012, 22:436-445.